



February 28, 2007

Kip Vought
Regulus Pharmaceutical Consulting, Inc.
4840 Pearl East Circle Suite 201E
Boulder, Colorado 80301

Dear Mr. Vought:

This is a correction to our acknowledgement letter of February 21, 2007. It contained typographical errors.

Your petition requesting the Food and Drug Administration to determine whether a previously listed drug Eloxatin (oxaliplatin for injection) Lyophilized Powder for Infusion, 50 and 100 mg vials has been voluntarily withdrawn from sale for safety or efficacy reasons, and to Accept an ANDA for a Generic Version of the Drug, was received by this office on 02/21/2007. It was assigned docket number 2007P-0062/CP1 and it was filed on 02/21/2007. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega
Division of Dockets Management
Office of Management Programs
Office of Management

2007P-0062

CR1